India Morning Newsletter, September 9-March 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

India Morning Newsletter, September 9

Sep 8, 2024 9:32 PM

To access a PDF version of this newsletter, please click here

If you would like to receive this newsletter via email, please register at:

https://solutions.refinitiv.com/MNCIndiaSubscriptionpage

For an index of our newsletters click on

Previous page： Alight Appoints Greg Giometti as Interim Chief Financial Officer Next page： Cybin to Transfer Listing to Nasdaq From NYSE American

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Alight Appoints Greg Giometti as Interim Chief Financial Officer

Mar 10, 2026

08:38 AM EST, 12/18/2025 (MT Newswires) -- Alight (ALIT) said Thursday it has appointed Greg Giometti as the company's interim chief financial officer, effective Jan. 9, 2026. Giometti succeeds Jeremy Heaton, who will depart Alight to pursue another opportunity, the company said. Giometti joined Alight in 2020 and currently serves as the company's senior vice president, head of financial planning...

Cybin to Transfer Listing to Nasdaq From NYSE American

Mar 10, 2026

08:39 AM EST, 12/18/2025 (MT Newswires) -- Cybin ( CYBN ) said Thursday that it will voluntarily transfer its listing to the Nasdaq Global Market from the NYSE American. Cybin ( CYBN ) said it expects its common shares will cease trading at the NYSE American at market close on Jan. 4 and start trading on Nasdaq at market open...

ATS Receives Approval From TSX for Normal Course Issuer Bid

Mar 10, 2026

08:39 AM EST, 12/18/2025 (MT Newswires) -- ATS (TSX and NYSE: ATS) on Thursday said that the Toronto Stock Exchange approved the company's notice of intention to make a normal course issuer bid (NCIB). Under the bid, the company will have the ability to buy back for cancellation up to a maximum of 8.2-million common shares, about 10% of the...

CAMP4 Therapeutics, GSK Collaborate to Develop RNA-Based Therapeutics for Neurodegenerative and Kidney Diseases

Mar 10, 2026

08:38 AM EST, 12/18/2025 (MT Newswires) -- CAMP4 Therapeutics ( CAMP ) said Thursday it has entered a research, collaboration and license agreement with GSK (GSK) to identify and develop antisense oligonucleotide drug candidates targeting neurodegenerative and kidney disease indications. Under the agreement, CAMP4 Therapeutics ( CAMP ) will receive upfront cash payment of $17.5 million and is eligible for...